What is the 13F Pro Quality Score for PBYI?

13F Pro ranks PUMA BIOTECHNOLOGY, INC. (PBYI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PBYI's current score at https://13fpro.ai/research/PBYI (free sign-up required for the full ranking).

Which hedge funds own the most PBYI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PBYI include ACORN CAPITAL ADVISORS,, BlackRock,, RENAISSANCE TECHNOLOGIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PBYI as soon as new 13F filings post.

Where does 13F Pro source PBYI data?

All PUMA BIOTECHNOLOGY, INC. fundamentals and ownership data come directly from SEC EDGAR. PUMA BIOTECHNOLOGY, INC. files with the SEC under CIK 1401667. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PBYI in?

PUMA BIOTECHNOLOGY, INC. (PBYI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PBYI research updated on 13F Pro?

PBYI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PUMA BIOTECHNOLOGY, INC.(PBYI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1401667 PBYI stock profile & AI dashboard →

13F Pro Quality Score

52.5/100

Rank #1,342 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.4/100

Profitability

59.6/100

Balance Sheet

76.5/100

Earnings Quality

30.0/100

Free Cash Flow

79.7/100

Institutional Flow

86.2/100

Revenue Scale

24.2/100

Dilution Risk

33.2/100

PBYI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PUMA BIOTECHNOLOGY, INC. (PBYI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBYI at 52.5/100 on a 32-signal composite quality model, placing it at rank #1,342 of 2,879 stocks — the top half of the AI-ranked universe. PBYI scores in the top quartile across institutional flow (86.2), free cash flow (79.7), balance sheet strength (76.5). Areas of concern include revenue scale (24.2) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PUMA BIOTECHNOLOGY, INC. reports quarterly revenue of $44.8M, net income of $-3.8M, free cash flow of $15.4M. Top institutional holders of PBYI by reported 13-F value include ACORN CAPITAL ADVISORS,, BlackRock,, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. PBYI trades on the Nasdaq exchange and files with the SEC under CIK 1401667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBYI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PUMA BIOTECHNOLOGY, INC. directly from SEC EDGAR. PUMA BIOTECHNOLOGY, INC.'s 13F Pro composite quality score has ranged between 19 and 68 since 2021, currently 52.5 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about PUMA BIOTECHNOLOGY, INC.

Quirks, history, and lore behind PBYI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Los Angeles, California · focused on oncology.
2
The Numbers
A small-cap biopharma with limited commercial revenue and a history of operating losses — the classic profile of a company betting everything on one approved drug.
3
The History
Founded in the early 2010s, the company spent years developing a therapy targeting a specific breast cancer mutation pathway before winning FDA approval.
4
The Secret
Its entire pipeline centers on irreversible HER2 inhibition — blocking a protein that drives some of the most aggressive forms of breast and gastric cancers.
5
The Lore
Its flagship drug, neratinib, targets HER2-positive patients who've already been through standard therapy — giving hope to women who thought they'd run out of options.
6
The Giveaway
The name sounds like a big cat sportswear brand, but this company is all about neratinib and fighting HER2-driven cancers — no sneakers involved.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$44.8M

Net Income

Q1 2026

$-3.8M

Free Cash Flow

Q1 2026

$15.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.9% YoY

$228.4MFY 2025

FY20 $225.1MFY21 $253.2MFY24 $230.5MFY25 $228.4M

Net Income

+2.8% YoY

$31.1MFY 2025

FY20 $-60.0MFY21 $29.1MFY24 $30.3MFY25 $31.1M

Operating Income

+20.5% YoY

$37.3MFY 2025

FY20 $-30.4MFY21 $1.3MFY24 $31.0MFY25 $37.3M

EPS (Diluted)

-1.6% YoY

$0.61FY 2025

FY20 $-1.52FY21 $-0.72FY24 $0.62FY25 $0.61

Total Assets

+1.4% YoY

$216.3MFY 2025

FY20 $244.2MFY21 $226.6MFY24 $213.3MFY25 $216.3M

Total Debt

-60.1% YoY

$45.2MFY 2025

FY20 $98.3MFY21 $102.0MFY24 $113.3MFY25 $45.2M

Op. Cash Flow

+7.4% YoY

$41.8MFY 2025

FY20 $773.0KFY21 $20.6MFY24 $38.9MFY25 $41.8M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2017	FY 2014
Revenue	$228.4M -0.9%	$230.5M -9.0%	$253.2M +12.5%	$225.1M +713.1%	$27.7M	—
Net Income	$31.1M +2.8%	$30.3M +4.0%	$29.1M +148.5%	$-60.0M +79.5%	$-292.0M -105.7%	$-142.0M
Operating Income	$37.3M +20.5%	$31.0M +2300.5%	$1.3M +104.2%	$-30.4M +89.6%	$-292.4M -105.5%	$-142.3M
EPS (Diluted)	$0.61 -1.6%	$0.62 +186.1%	$-0.72 +52.6%	$-1.52	—	—
Total Assets	$216.3M +1.4%	$213.3M -5.8%	$226.6M -7.2%	$244.2M +47.5%	$165.5M +1.7%	$162.8M
Total Debt	$45.2M -60.1%	$113.3M +11.1%	$102.0M +3.8%	$98.3M +102.8%	$48.5M	—
Operating Cash Flow	$41.8M +7.4%	$38.9M +88.5%	$20.6M +2571.4%	$773.0K +100.4%	$-172.5M -46.2%	$-117.9M

AI Insight: PBYI Ratio Trends

Q1 2026 swung sharply to -8.5% operating margin, breaking a four-quarter recovery streak that peaked at 22.7% in Q4 2025.

• Operating margin recovered from -4.6% in Q2 2024 to 22.7% in Q4 2025, then collapsed to -8.5% in Q1 2026.

• D/E ratio improved steadily from 2.80 in Q2 2024 to just 0.18 in Q1 2026, signaling meaningful deleveraging.

• ROIC turned negative at -10.1% in Q1 2026 after reaching 39.0% in Q4 2025, reversing capital efficiency gains.

• TTM operating margin of 13.0% and ROIC of 19.5% suggest the Q1 2026 loss may reflect seasonal or one-off pressure.

⚠ Q1 2026 OpMargin of -8.5% mirrors Q2 2024's trough — confirm whether this is seasonal pattern or structural deterioration.

⚠ ROE swung from +41.2% in Q4 2025 to -11.7% in Q1 2026 — magnitude of swing warrants scrutiny of one-off items.

⚠ Continued D/E compression to 0.18 reduces financial risk; monitor whether balance sheet strength persists if losses deepen.

Get alerted when PBYI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PUMA BIOTECHNOLOGY, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PBYI

ACORN CAPITAL ADVISORS, LLC
$26.4M4,131,299 sh
BlackRock, Inc.
$23.0M3,598,952 sh
RENAISSANCE TECHNOLOGIES LLC
$12.4M1,942,413 sh
AMERICAN CENTURY COMPANIES INC
$12.2M1,916,346 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.6M1,817,681 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$11.1M1,734,649 sh
MILLENNIUM MANAGEMENT LLC
$9.4M1,477,519 sh
DIMENSIONAL FUND ADVISORS LP
$9.2M1,436,106 sh
O'SHAUGHNESSY ASSET MANAGEMENT, LLC
$7.3M1,138,169 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.5M1,017,342 sh

Fund	Value	Shares
ACORN CAPITAL ADVISORS, LLC	$26.4M	4,131,299
BlackRock, Inc.	$23.0M	3,598,952
RENAISSANCE TECHNOLOGIES LLC	$12.4M	1,942,413
AMERICAN CENTURY COMPANIES INC	$12.2M	1,916,346
VANGUARD CAPITAL MANAGEMENT LLC	$11.6M	1,817,681
VANGUARD PORTFOLIO MANAGEMENT LLC	$11.1M	1,734,649
MILLENNIUM MANAGEMENT LLC	$9.4M	1,477,519
DIMENSIONAL FUND ADVISORS LP	$9.2M	1,436,106
O'SHAUGHNESSY ASSET MANAGEMENT, LLC	$7.3M	1,138,169
GEODE CAPITAL MANAGEMENT, LLC	$6.5M	1,017,342

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PBYI on your watchlist

Track score changes the day PUMA BIOTECHNOLOGY, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PBYI a good stock to buy?

13F Pro's AI-powered analysis of PUMA BIOTECHNOLOGY, INC. (PBYI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PBYI are available on the PBYI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PBYI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PBYI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PUMA BIOTECHNOLOGY, INC.'s investment landscape.